louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03695692: Effects of Connective Tissue Massage in Women With Overactive Bladder
Official title: Assistant Professor, Physioterapist, PhD
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Overactive Bladder
Lead sponsor: Ataturk Training and Research Hospital
Sponsor class: OTHER
First posted: 2018-10-04
Enrollment: 40
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to compare the effects of pelvic floor muscle trainig with connective tissue massage and only pelvic floor muscle training in women with overactive bladder


Eligibility criteria: Inclusion Criteria:

* 18 to 65 years of age,
* having overactive bladder
* being volunteer

Exclusion Criteria:

* being in the period of pregnancy or breastfeeding,
* having an accompanying neurological disease, presence of a mental issue that would prevent cooperation in examinations and/or implementations, history of acute infectionor presence of a malignce

Primary outcomes:
measure: overactive bladder symptoms measured by Overactive Bladder Questionnaire_V8
timeFrame: Change from baseline bladder symptoms at 6 weeks
Secondary outcomes:
measure: urgency complaint assessed with The patient's Perception of Intensity of Urgency Scale
timeFrame: Change from baseline urgency complaints at 6 weeks
measure: quality of life assessed with King's Health Questionnaire (KHQ)
timeFrame: Change from baseline quality of life at 6 weeks
measure: pelvic floor muscle strength measured with perineometer
timeFrame: Change from baseline pelvic floor muscle strength at 6 weeks
measure: diurnal urinary frequency, nocturia, maximum urinary volume, the number of urinary leakage and pad changes measured with voiding dairy
timeFrame: Change from baseline diurnal urinary frequency, nocturia, maximum urinary volume, the number of urinary leakage and pad changes at 6 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Yildirim Beyazit University
Study officials:
affiliation: Ankara Yildirim Beyazıt University
name: Seyda TOPRAK CELENAY
role: PRINCIPAL_INVESTIGATOR
affiliation: Beykent University
name: Yasemin Karaaslan
role: STUDY_CHAIR
affiliation: Kahramanmaras Sutcu Imam University
name: Faruk Kucukdurmaz
role: STUDY_CHAIR
References:
Clinical trial NCT05016492: Interactive Digital Game for Improving Visual Perceptual Defects in Children With Developmental Disability
Official title: Interactive Digital Game for Improving Visual Perceptual Defects in Children With Developmental Disability: Evaluation of Efficacy and User Satisfaction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Developmental Disability
Lead sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Sponsor class: OTHER
First posted: 2021-08-23
Enrollment: 23
Sex: ALL
Minimum age (years): 4
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Visual perceptual defects in children can negatively affect their activities of daily living.The aims of this study were to develop and evaluate an interactive digital game system for correcting visual perceptual defects and to evaluate the effectiveness of the proposed system.


Eligibility criteria: Inclusion Criteria:

* Record of developmental disability diagnosis
* Ability to understand instructions
* TVPS-3 score lower than 25% of the norm reference and diagnosis of visual perceptual defect
* Test of Nonverbal Intelligence-3rd Edition score higher than 70

Exclusion Criteria:

* Did not follow or understand the instructions for participating in the study
* Had severe defects in vision, hearing, etc.

Primary outcomes:
measure: Test of Visual Perceptual Scale-3(TVPS-3)
timeFrame: 4 weeks
measure: User satisfaction survey
timeFrame: 4 weeks
measure: Test of the visual-perceptual interactive game system
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University
Study officials:
References:
citation: Wu WL, Huang YL, Liang JM, Chen CH, Wang CC, Ho WH. Interactive Digital Game for Improving Visual-Perceptual Defects in Children With a Developmental Disability: Randomized Controlled Trial. JMIR Serious Games. 2022 Apr 15;10(2):e34756. doi: 10.2196/34756.
Clinical trial NCT06641492: A RCT Evaluating a Chatbot in Increasing Physical Activity Among Older Adults
Official title: A Randomized Controlled Trial Evaluating a Trans-Theoretical-Model-based Online Intervention Delivered by Fully-automated Chatbot in Increasing Physical Activity Among Inactive Community-dwelling People Aged ≥65 Years
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Physical Inactivity
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2024-10-15
Enrollment: 278
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study will compare the efficacy of a Chatbot-delivered stage of changes (SOC)-tailored online intervention (intervention group) versus a Chatbot-delivered non-SOC-tailored online intervention in increasing the prevalence of meeting WHO recommended physical activity level six months after completion of the intervention among inactive community-dwelling individuals aged ≥65 yeas. In the intervention group, the Chatbot will assess participants' physical activity level and SOC regarding PA and automatically deliver interventions tailor to their SOC every week for 12 weeks. In the control group, the Chatbot will not assess participants' SOC. It will assess participants' physical activity level and provides a standard intervention covering general information about physical activity for older adults, which is not tailoring to participants'SOC every week for 12 weeks. All participants will be followed up after completion of the interventions (T1) and six months after T1 (T2).


Eligibility criteria: Inclusion Criteria:

* Aged ≥65 years,
* Having a Hong Kong ID,
* Chinese speaking,
* Not meet the WHO recommended level of MVPA
* Willing to be followed by telephone at 3 and 9 months,
* Having a smartphone
* Able to send and read text/voice message via smartphone.
* Willing to wear an accelerometer for a week at T0, T1 and T2.

Exclusion Criteria:

* Blindness or deafness,
* Having been diagnosed with major psychiatric illness (schizophrenia or bipolar disorder) or dementia,
* Score ≥1 in the Chinese version of the Physical Activity Readiness Questionnaire (PAR-Q)
* Score ≤16 in the validated telephone version of the Cantonese Mini-mental State Examination (T-CMMSE)

Primary outcomes:
measure: Meeting WHO recommended level of physical activity
timeFrame: 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Centre for Health Behaviours Research, the Chinese University of Hong Kong
Study officials:
affiliation: Centre for Health Behaviours Research, the Chinese University of Hong Kong
name: Zixin Wang, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06907992: A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia
Official title: Short-Course Antifungal Therapy vs Standard of Care (14 Day Therapy) for Uncomplicated Candidemia (SCAT)
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Candidemia
Keywords: candidemia
uncomplicated candidemia
antifungal therapy
echinocandin
caspofungin
micafungin
rezafungin
anidulafungin
Lead sponsor: Augusta University
Sponsor class: OTHER
First posted: 2025-04-03
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Participants will be recruited from:

A. Inpatient settings based on positive blood cultures for candidemia. B. Daily review of microbiology labs C. Referrals from investigators, ICUs and hospital unit personnel

Brief summary: The goal of this clinical trial is to assess whether a seven-day course of standard of care (echinocandin) antifungal therapy is non-inferior to a 14-day course of echinocandin antifungal therapy in patients with uncomplicated candidemia in terms of clinical, mycologic, adverse events and all cause mortality.


Eligibility criteria: Inclusion Criteria:

1. Patients ≥ 18 years of age
2. Uncomplicated candidemia (positive blood culture only). No evidence of invasive candidiasis at day 1 or until day 7.
3. Received \< 5 days of prior antifungal therapy
4. Informed Consent for randomization
5. Patients that did not consent to randomization have consented to be used as a natural history (controls) and will allow collection of available data from the medical record.

Exclusion Criteria:

1. Inadequate source control (e.g., unable to remove endovascular devices, urinary catheters).
2. Invasive candidiasis of any type (e.g., deep seated candidiasis from sources other than blood)
3. Abnormal LFTs \> 10-fold
4. Greater than 5 days of prior antifungal therapy
5. Endovascular devices that cannot be removed.
6. Immunocompromised patients (AIDS/HIV; solid organ transplant, bone marrow transplant patients, oncology patients receiving chemotherapy, neutropenic patients (ANC of \< 1,500 cells/L
7. Neutropenic at time of consent (what does this mean)
8. Break-through candidemia (people with prior candidemia who relapsed) after treatment with antifungal therapy)
9. Unable to provide informed consent from either the patient or legally authorized authority (LAR)
10. Expected mortality within 96 hours

Primary outcomes:
measure: Eradication of candida from the blood at day 7 or day 14
timeFrame: 14 Days
Secondary outcomes:
Other outcomes:
Locations:
city: Augusta
country: United States
facility: Augusta University
state: Georgia
Study officials:
affiliation: Augusta University
name: Jose Vazquez, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01421992: Methylphenidate in Myotonic Dystrophy Type 1
Official title: Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Dystrophia Myotonica 1
Keywords: randomized
double-blind
crossover
methylphenidate
excessive daytime sleepiness
Lead sponsor: Laval University
Sponsor class: OTHER
First posted: 2011-08-23
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether methylphenidate is effective in the treatment of excessive daytime sleepiness due to myotonic dystrophy type 1 (DM1).

Detailed description: Myotonic dystrophy type 1 (DM1) is a multisystemic disorder characterized by muscle weakness, myotonia, and the involvement of several systems. Hypersomnolence is one of the most frequently reported symptoms in patients with DM1 and often lead to handicap such as cessation of employment and withdrawal from social activities.The current investigation represents a prospective, double-blind, randomized, crossover, placebo-controlled study designed to evaluate the efficacy of methylphenidate for the treatment of excessive daytime sleepiness (EDS) in adults with DM1.

Eligibility criteria: Inclusion Criteria:

* adults
* Epworth score ≥ 10
* Diagnosis of myotonic dystrophy type 1

Exclusion Criteria:

* hypersensibility to methylphenidate
* Pregnancy
* Patients who receive drugs that interfere with methylphenidate
* Cognitive impairment
* Sleep apnea

Primary outcomes:
measure: Change from baseline of excessive daytime sleepiness
timeFrame: 3 weeks after treatment
Secondary outcomes:
measure: Change from baseline of POMS, Rand36-Item Health survey and mean sleep latency
timeFrame: 3 weeks after treatment
Other outcomes:
Locations:
city: Quebec
country: Canada
facility: Institute of Readaptation in Physical Deficiency
Study officials:
affiliation: University Laval
name: Jack J Puymirat, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Puymirat J, Bouchard JP, Mathieu J. Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: a 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial. Clin Ther. 2012 May;34(5):1103-11. doi: 10.1016/j.clinthera.2012.03.060.
Clinical trial NCT03175692: Rapid Genetic Diagnosis Employing Next Generation Sequencing for Critical Illness in Infants and Children
Official title: Rapid Genetic Diagnosis Employing Next Generation Sequencing for Critical Illness in Infants and Children
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Congenital Metabolic Disorder
Acute Disease
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: Ministry of Science and Technology, Taiwan
First posted: 2017-06-05
Enrollment: 150
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children and newborn patients at National Taiwan University Hospital

Brief summary: Under the joint efforts of genetic and intensive expert, to establish the high-throughput whole exon sequencing(WES) and analysis all the possible pathogenic genes. To provide patient with the appropriate treatment for genetic disease. Besides, it can identify the genetic factor of idiosyncrasy or susceptibility to explain the medical difficulties and give patients personalized advice.


Eligibility criteria: Inclusion Criteria:

* Pediatric patients admitted to intensive care unit
* Infants with abnormal newborn screening result that is medical emergency

Exclusion Criteria:

* Participants or parents who cannot comply with study

Primary outcomes:
measure: Sensitivity of whole exome sequencing in detecting causative mutations
timeFrame: 10 weeks
Secondary outcomes:
measure: Time frame of mutation identified after receipt of the sample
timeFrame: 10 weeks
measure: Percentage of mutation identified within 7 days after receipt of the sample
timeFrame: 10 weeks
measure: Changes in healthcare decision after disclosure of the result
timeFrame: 6 months
measure: Parents/family's attitude about exome sequencing
timeFrame: 6 months
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: Department of Pediatrics and Medical Genetics, National Taiwan University Hospital
name: Wuh-Liang Hwu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04146792: Expand Your Horizon: An Online Writing Intervention for Women
Official title: Expand Your Horizon: An Online Writing Intervention for Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Body Image
Lead sponsor: Virginia Commonwealth University
Sponsor class: OTHER
Collaborators: name: Society for the Psychological Study of Social Issues
First posted: 2019-10-31
Enrollment: 163
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this research study is to test a new writing-based intervention that helps young adult women increase their body acceptance and fosters creativity.

Detailed description: In this study, participants will be asked to do the following things:

1. Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
2. \~1-hour long online surveys immediately after the program (1 week), and 1 week after the program. Questions will ask about eating behaviors and attitudes, body image, feelings of weight stigma, and mental health.
3. Be contacted through email to remind participants to complete the writing assignments/survey

Eligibility criteria: Inclusion Criteria:

* women ages 18 to 25 years
* enrolled in postsecondary education at VCU
* endorse some degree of WBI (as measured by the WBI-M) or body image concerns

Exclusion Criteria:

* men
* pregnant women

Primary outcomes:
measure: Change in weight bias internalization (WBI)
timeFrame: baseline to 2 weeks
Secondary outcomes:
measure: Change in body functionality appreciation
timeFrame: baseline to 2 weeks
measure: Change in body image dissatisfaction
timeFrame: Baseline to 2 weeks
measure: Change in objectified body consciousness
timeFrame: Baseline to 2 weeks
measure: Change in self-compassion
timeFrame: Baseline to 2 weeks
measure: Change in depression
timeFrame: Baseline to 2 weeks
measure: Change in anxiety
timeFrame: Baseline to 2 weeks
measure: Change in stress
timeFrame: Baseline to 2 weeks
measure: Change in healthcare stress
timeFrame: Baseline to 2 weeks
measure: Change in healthcare avoidance
timeFrame: Baseline to 2 weeks
measure: Change in physical activity acceptance
timeFrame: Baseline to 2 weeks
measure: Change in global eating disorder symptoms
timeFrame: Baseline to 2 weeks
Other outcomes:
Locations:
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
Study officials:
affiliation: Virginia Commonwealth University
name: Suzanne Mazzeo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02994992: Sun Protection Factor Assay (316/2016)
Official title: Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sunscreening Agents
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2016-12-16
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: To evaluate the Sun Protection Factor efficacy on human skin.


Eligibility criteria: Inclusion Criteria:

* Fitzpatrick Skin Type l, ll and/or lll for UVB testing. Fitzpatrick Skin Type ll, lll and/or lV for UVA testing.
* Male and female.
* Aged between 18-70 years old.
* Good health as determined from the HRL SHF (Subject History Form).
* Signed and dated Informed Consent Form
* Signed and dated HIPAA (Health Insurance Portability and Accountability Act) form.
* An unambiguous MED (Minimal Erythema Dose) or MPPD (Minimal Persistent Pigment Darkening Dose).

Exclusion Criteria:

* Subjects on test at any other research laboratory or clinic.
* Known allergy or sensitivity to sunscreens, cosmetics and toiletries, topical drugs and/or ultraviolet light.
* Pre-existing dermatologic conditions which have been diagnosed by a medical professional (e.g. psoriasis, eczema, etc.) which would interfere with this study.
* Pre-existing other medical conditions (e.g. adult asthma, diabetes).
* Treatment with antihistamines or corticosteroids within one week prior to initiation of the test.
* Treatment with antibiotics within two weeks prior to initiation of the test.
* Chronic medication which could affect the results of the study.
* Known pregnant or nursing women.

Primary outcomes:
measure: Minimal Erythema Dose (MED)
timeFrame: Up to 15 minutes
measure: Minimal Persistent Pigment Darkening Dose (MPPD)
timeFrame: Up to 15 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Union
country: United States
state: New Jersey
Study officials:
References:
Clinical trial NCT06465992: Liposomal Bupivacaine With Dexamethasone for Foot Surgery
Official title: Single-Shot Liposomal Bupivacaine vs. Liposomal Bupivacaine Combined With Dexamethasone Prior to Foot and Ankle Procedures: A Prospective Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE4
Conditions: Foot Surgery
Ankle Surgery
Post Operative Pain
Popliteal Nerve Block
Lead sponsor: Rothman Institute Orthopaedics
Sponsor class: OTHER
First posted: 2024-06-20
Enrollment: 126
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to understand the ideal formulation to utilize in saphenous nerve and popliteal nerve blocks for foot and ankle procedures. It will examine the use of liposomal bupivacaine alone or liposomal bupivacaine with dexamethasone prior to foot and ankle procedures in peripheral nerve blocks. We will compare liposomal bupivacaine (Exparel) and liposomal bupivacaine (Exparel) combined with dexamethasone to determine if the addition of dexamethasone significantly decreases postoperative narcotic use and prolongs analgesic effects when administered in a popliteal and saphenous block prior to foot and ankle orthopedic procedures.


Eligibility criteria: Inclusion Criteria:

* Participants with foot and ankle procedures at Jefferson Surgery Center, Navy Yard
* Participants with foot and ankle orthopedic procedures requiring a preoperative nerve block
* Age 18 and older
* English speaking
* Ability to complete surveys by phone or in person
* Ability to provide informed consent

Exclusion Criteria:

* Revision foot and ankle cases
* Allergies to study medications
* Non-English speakers
* Known alcohol or narcotic abuse history
* Existing contract with a pain specialist due to underlying preoperative pain syndrome
* Preoperative opioid use within the 3 months prior to surgery
* Participants who are pregnant, plan to become pregnant, or are breastfeeding.

Primary outcomes:
measure: Amount of pain medication used after surgery
timeFrame: 14 days
measure: Pain level after surgery
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Rothman Orthopaedic Institute
state: Pennsylvania
Study officials:
References:
Clinical trial NCT02497092: Different Intravitreal Injection Techniques and Pain Level
Official title: Effect of Different Injection Techniques on Pain Level in Intravitreal Injections
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Injection Site Discomfort
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2015-07-14
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to determine whether certain intravitreal injection techniques cause less pain than others and would therefore be beneficial for the patient's well being.


Eligibility criteria: Inclusion Criteria:

* Patients receiving intravitreal anti vascular endothelial growth factor (VEGF) injections
* Informed consent

Exclusion Criteria:

* Dementia or any other reason for cognitive deterioration
* Technical limitations not allowing injecting by the protocol

Primary outcomes:
measure: Pain during the injection as measured by the "Pain numeric rating scale"
timeFrame: Up to 2 minutes after the injection
Secondary outcomes:
Other outcomes:
Locations:
city: Petah Tikva
country: Israel
facility: Rabin Medical Center
Study officials:
affiliation: Rabin Medical Center
name: Amir Sternfeld, MD
role: PRINCIPAL_INVESTIGATOR
References: